Cargando…

Residual Disease After Primary Surgical Treatment for Advanced Epithelial Ovarian Cancer, Part 2: Network Meta-analysis Incorporating Expert Elicitation to Adjust for Publication Bias

Previous work has identified a strong association between the achievements of macroscopic cytoreduction and improved overall survival (OS) after primary surgical treatment of advanced epithelial ovarian cancer. Despite the use of contemporary methodology, resulting in the most comprehensive currentl...

Descripción completa

Detalles Bibliográficos
Autores principales: Bryant, Andrew, Grayling, Michael, Elattar, Ahmed, Gajjar, Ketankumar, Craig, Dawn, Vale, Luke, Naik, Raj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Journal of Therapeutics 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9812412/
https://www.ncbi.nlm.nih.gov/pubmed/36048531
http://dx.doi.org/10.1097/MJT.0000000000001548
_version_ 1784863720176877568
author Bryant, Andrew
Grayling, Michael
Elattar, Ahmed
Gajjar, Ketankumar
Craig, Dawn
Vale, Luke
Naik, Raj
author_facet Bryant, Andrew
Grayling, Michael
Elattar, Ahmed
Gajjar, Ketankumar
Craig, Dawn
Vale, Luke
Naik, Raj
author_sort Bryant, Andrew
collection PubMed
description Previous work has identified a strong association between the achievements of macroscopic cytoreduction and improved overall survival (OS) after primary surgical treatment of advanced epithelial ovarian cancer. Despite the use of contemporary methodology, resulting in the most comprehensive currently available evidence to date in this area, opponents remain skeptical. AREAS OF UNCERTAINTY: We aimed to conduct sensitivity analyses to adjust for potential publication bias, to confirm or refute existing conclusions and recommendations, leveraging elicitation to incorporate expert opinion. We recommend our approach as an exemplar that should be adopted in other areas of research. DATA SOURCES: We conducted random-effects network meta-analyses in frequentist and Bayesian (using Markov Chain Montel Carlo simulation) frameworks comparing OS across residual disease thresholds in women with advanced epithelial ovarian cancer after primary cytoreductive surgery. Elicitation methods among experts in gynecology were used to derive priors for an extension to a previously reported Copas selection model and a novel approach using effect estimates calculated from the elicitation exercise, to attempt to adjust for publication bias and increase confidence in the certainty of the evidence. THERAPEUTIC ADVANCES: Analyses using data from 25 studies (n = 20,927 women) all showed the prognostic importance of complete cytoreduction (0 cm) in both frameworks. Experts accepted publication bias was likely, but after adjustment for their opinions, published results overpowered the informative priors incorporated into the Bayesian sensitivity analyses. Effect estimates were attenuated but conclusions were robust in all analyses. CONCLUSIONS: There remains a strong association between the achievement of complete cytoreduction and improved OS even after adjustment for publication bias using strong informative priors formed from an expert elicitation exercise. The concepts of the elicitation survey should be strongly considered for utilization in other meta-analyses.
format Online
Article
Text
id pubmed-9812412
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Journal of Therapeutics
record_format MEDLINE/PubMed
spelling pubmed-98124122023-01-12 Residual Disease After Primary Surgical Treatment for Advanced Epithelial Ovarian Cancer, Part 2: Network Meta-analysis Incorporating Expert Elicitation to Adjust for Publication Bias Bryant, Andrew Grayling, Michael Elattar, Ahmed Gajjar, Ketankumar Craig, Dawn Vale, Luke Naik, Raj Am J Ther Therapeutic Advance Previous work has identified a strong association between the achievements of macroscopic cytoreduction and improved overall survival (OS) after primary surgical treatment of advanced epithelial ovarian cancer. Despite the use of contemporary methodology, resulting in the most comprehensive currently available evidence to date in this area, opponents remain skeptical. AREAS OF UNCERTAINTY: We aimed to conduct sensitivity analyses to adjust for potential publication bias, to confirm or refute existing conclusions and recommendations, leveraging elicitation to incorporate expert opinion. We recommend our approach as an exemplar that should be adopted in other areas of research. DATA SOURCES: We conducted random-effects network meta-analyses in frequentist and Bayesian (using Markov Chain Montel Carlo simulation) frameworks comparing OS across residual disease thresholds in women with advanced epithelial ovarian cancer after primary cytoreductive surgery. Elicitation methods among experts in gynecology were used to derive priors for an extension to a previously reported Copas selection model and a novel approach using effect estimates calculated from the elicitation exercise, to attempt to adjust for publication bias and increase confidence in the certainty of the evidence. THERAPEUTIC ADVANCES: Analyses using data from 25 studies (n = 20,927 women) all showed the prognostic importance of complete cytoreduction (0 cm) in both frameworks. Experts accepted publication bias was likely, but after adjustment for their opinions, published results overpowered the informative priors incorporated into the Bayesian sensitivity analyses. Effect estimates were attenuated but conclusions were robust in all analyses. CONCLUSIONS: There remains a strong association between the achievement of complete cytoreduction and improved OS even after adjustment for publication bias using strong informative priors formed from an expert elicitation exercise. The concepts of the elicitation survey should be strongly considered for utilization in other meta-analyses. American Journal of Therapeutics 2022-11-01 /pmc/articles/PMC9812412/ /pubmed/36048531 http://dx.doi.org/10.1097/MJT.0000000000001548 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Therapeutic Advance
Bryant, Andrew
Grayling, Michael
Elattar, Ahmed
Gajjar, Ketankumar
Craig, Dawn
Vale, Luke
Naik, Raj
Residual Disease After Primary Surgical Treatment for Advanced Epithelial Ovarian Cancer, Part 2: Network Meta-analysis Incorporating Expert Elicitation to Adjust for Publication Bias
title Residual Disease After Primary Surgical Treatment for Advanced Epithelial Ovarian Cancer, Part 2: Network Meta-analysis Incorporating Expert Elicitation to Adjust for Publication Bias
title_full Residual Disease After Primary Surgical Treatment for Advanced Epithelial Ovarian Cancer, Part 2: Network Meta-analysis Incorporating Expert Elicitation to Adjust for Publication Bias
title_fullStr Residual Disease After Primary Surgical Treatment for Advanced Epithelial Ovarian Cancer, Part 2: Network Meta-analysis Incorporating Expert Elicitation to Adjust for Publication Bias
title_full_unstemmed Residual Disease After Primary Surgical Treatment for Advanced Epithelial Ovarian Cancer, Part 2: Network Meta-analysis Incorporating Expert Elicitation to Adjust for Publication Bias
title_short Residual Disease After Primary Surgical Treatment for Advanced Epithelial Ovarian Cancer, Part 2: Network Meta-analysis Incorporating Expert Elicitation to Adjust for Publication Bias
title_sort residual disease after primary surgical treatment for advanced epithelial ovarian cancer, part 2: network meta-analysis incorporating expert elicitation to adjust for publication bias
topic Therapeutic Advance
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9812412/
https://www.ncbi.nlm.nih.gov/pubmed/36048531
http://dx.doi.org/10.1097/MJT.0000000000001548
work_keys_str_mv AT bryantandrew residualdiseaseafterprimarysurgicaltreatmentforadvancedepithelialovariancancerpart2networkmetaanalysisincorporatingexpertelicitationtoadjustforpublicationbias
AT graylingmichael residualdiseaseafterprimarysurgicaltreatmentforadvancedepithelialovariancancerpart2networkmetaanalysisincorporatingexpertelicitationtoadjustforpublicationbias
AT elattarahmed residualdiseaseafterprimarysurgicaltreatmentforadvancedepithelialovariancancerpart2networkmetaanalysisincorporatingexpertelicitationtoadjustforpublicationbias
AT gajjarketankumar residualdiseaseafterprimarysurgicaltreatmentforadvancedepithelialovariancancerpart2networkmetaanalysisincorporatingexpertelicitationtoadjustforpublicationbias
AT craigdawn residualdiseaseafterprimarysurgicaltreatmentforadvancedepithelialovariancancerpart2networkmetaanalysisincorporatingexpertelicitationtoadjustforpublicationbias
AT valeluke residualdiseaseafterprimarysurgicaltreatmentforadvancedepithelialovariancancerpart2networkmetaanalysisincorporatingexpertelicitationtoadjustforpublicationbias
AT naikraj residualdiseaseafterprimarysurgicaltreatmentforadvancedepithelialovariancancerpart2networkmetaanalysisincorporatingexpertelicitationtoadjustforpublicationbias